The AR Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the genetically stable 769-P Homo sapiens renal cell carcinoma cell line, engineered for targeted disruption of the androgen receptor (AR) gene. This product offers a heterogeneous pool of AR-null cells, faithfully preserving population-level diversity to avoid clonal biases. CRISPR/Cas9-mediated gene disruption ensures efficient ablation of functional AR protein, creating a versatile loss-of-function system for rigorous analysis of androgen signaling in a kidney cancer context.
The 769-P host line is a human clear cell renal cell carcinoma model harboring a VHL tumor suppressor mutation, characteristic of the majority of sporadic renal cancers. This adherent epithelial cell line retains key features of kidney tumor biology and is extensively used in cancer research to explore mechanisms of tumorigenesis, metastasis, and therapeutic resistance. Its VHL-deficient background provides a unique platform to study androgen receptor function within the aberrant HIF-driven signaling milieu of renal cell carcinoma.
Androgen receptor (AR) is a nuclear hormone receptor that acts as a ligand-activated transcription factor. Upon binding androgens such as testosterone and dihydrotestosterone, AR dissociates from chaperone complexes (HSP90, HSP70), translocates to the nucleus, and recruits coactivators including NCOA1 and NCOA2 to promoter regions. This facilitates transcription of key target genes, such as KLK3 (PSA), TMPRSS2, NKX3-1, and FKBP5. AR activity is positively regulated by upstream kinases AKT and MAPK1/3, and by growth factors EGF and IGF-1, while interacting transcription factors like FOXA1 and GATA2 modulate its genomic binding. Consequently, AR integrates signals from MAPK, PI3K-AKT, Wnt, and TGF-beta pathways to control cell growth, differentiation, and survival.
In the 769-P renal cell carcinoma context, AR knockout enables precise dissection of androgen signaling contributions to kidney cancer biology. Although traditionally studied in prostate cancer, AR expression in RCC may influence tumor progression and drug sensitivity. This model facilitates investigation of AR-dependent proliferation, migration, and survival in a VHL-mutant background, potentially uncovering therapeutic vulnerabilities or resistance mechanisms linked to crosstalk with the hyperactive PI3K-AKT pathway often observed in renal malignancies.
The AR Knockout 769-P Polyclonal Cells support a wide array of downstream applications, including western blotting and RT-qPCR for confirmation of AR gene disruption and target expression analysis. Chromatin immunoprecipitation (ChIP-qPCR) and reporter gene assays enable detailed studies of AR-mediated transcriptional regulation. Functional phenotyping using proliferation, migration, and invasion assays, along with drug sensitivity profiling, permits screening of androgen receptor modulators and evaluation of pathway crosstalk. This cell model is an essential resource for advancing renal cancer research and androgen signaling studies. For more information, please contact Ascent Research.
